Home › NCT06639503
Genicular Nerve Block After Open Reduction Internal Fixation of Tibial Plateau
Genicular Nerve Block for Analgesia After Open Reduction Internal Fixation of Tibial Plateau Fractures: A Prospective, Randomized Controlled Trial
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: • Any adult patient (ages 18 and over) undergoing open reduction internal fixation of an acute isolated tibial plateau fracture Exclusion Criteria: * Subjects younger than 18 * Polytraumatized Subjects * Subjects with pathologic fractures * Subjects with tibial plateau fractures treated nonoperatively * Subjects with tibial plateau fractures treated operatively but with re-operations at the same site * Subjects with open fractures * Subjects with fracture-dislocations * Subjects with active or history of anxiety * Subjects with visual analog scale anxiety score ≥ 7 measured preoperatively * Subjects with chronic pain syndromes * Subjects with chronic opioid use * Subjects with illicit drug use disorder * Subjects with alcohol abuse disorder * Subjects with kidney disease precluding use of ketorolac * Subjects with liver disease precluding the use of acetaminophen * Subjects with allergy to acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDs), opiates or local anesthesia * Subjects with inability to provide a visual analog scale score postoperatively * Subjects with contraindications to receiving peripheral nerve blocks, including relevant neurologic deficits, active infection at sites of injections - re-operation at the same site
About the study
The investigators are conducting this research study to find better ways of treating pain following knee surgery. There is a standard (accepted) approach, which involves injection of numbing medication into the area around the participant surgical incision. The investigators hope to discover if providing numbing medication to a nerve that controls pain in a larger area of the knee (a nerve block), might be better at post-operative pain control.
What is being tested
- Bupivacain (drug)
Sponsor: University of Chicago · Participants: 38 · Started: Nov 1, 2024
Contact the study team
- Anthony Christiano, MD · Phone: 773-834-3531
Official record on ClinicalTrials.gov — NCT06639503
Locations in the U.S.
| Illinois | University of Chicago, Chicago |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.